Virtual Investor Event

Bettina serves as CENTOGENE’s Chief Data Officer (CDO). Bringing 15 years of international industry experience and product-centricity, Bettina is responsible for ensuring that the management, governance, and commercialization of CENTOGENE’s data-based knowledge meets the highest quality standards.

Bettina previously served as Managing Director of Data Products & Services at Springer Nature – overseeing data and product development, as well as commercialization of five data products for R&D, including the AdisInsight databases for drug development. Bettina holds an undergraduate degree in Biochemistry from the University of Tübingen with practical research at Harvard Institutes of Medicine, as well as a master’s degree in Molecular Biology from the International Max Planck Research School. She started her career at McKinsey & Company and INSEAD Business School.

Bettina also holds board seats at Deepmatter Group Plc, a laboratory digitalization company focused on big data and experimental chemistry, as well as at Eagle Genomics Ltd., an innovator of data analysis software for life sciences and a Microsoft Genomics Partner.

Max serves as CENTOGENE’s Chief Commercial Officer Diagnostics. Bringing over two decades of Experience, Max has the overall responsibility of driving the company’s Diagnostic business strategy and growth. He joins CENTOGENE from Roche Diagnostics, where he most recently served as Global Head of Medical Affairs of its Sequencing Business Unit. Within this role, he was responsible for developing and executing the medical strategy across different countries and disease areas, such as Oncology and Women’s Health. He came to Roche following the acquisition of Silicon Valley startup Ariosa Diagnostics Inc., where after a successful career in academic medicine, he helped build a leading global NIPT business.

Prior to his medical career, Max worked as a Management Consultant for McKinsey & Company – developing and implementing strategies and solutions to overcome complex challenges in the pharmaceutical and biotechnology industry.

Furthermore, he holds a medical degree from the University of Vienna and is board-certified with habilitation in Obstetrics and Gynecology and sub-specialty training in Maternal-Fetal Medicine, as well as certification in Clinical Genetics.

Prof. Peter Bauer, M.D., serves as CENTOGENE's Chief Medical and Genomic Officer, where he combines an extensive clinical and medical understanding of genetic testing with an excellent knowledge of the latest scientific developments.

Peter is passionate about turning medical questions into complete and fast analytical processes – ensuring that medically-driven results are brought to clinicians and patients immediately.

He received his board certification in Human Genetics in 2006 and previously headed the Molecular Diagnostic Laboratory at the Institute of Medical Genetics and Applied Genomics at the University Hospital Tübingen. Peter has authored more than 250 publications in Neurogenetics, Oncogenetics, Cardiogenetics, and Sequencing Technology.

Justin, as Senior Vice President of Business Development at CENTOGENE, leads a global team in developing the company’s pharmaceutical partnership strategy with the goal of maximizing value through accelerating and de-risking orphan drug programs for rare genetic diseases. Prior to CENTOGENE, Justin was the Director of Business Development at Synthetic Genomics, Inc (SGI) and responsible for pharma and life science partnerships and collaborations. He draws from more than 10 years as a cell biologist, having worked in preclinical drug discovery. His broad experience as a scientist and in scaling life science and biotechnology companies to meet the demands of their partners provides a unique perspective and helps CENTOGENE to build further value as a company.